Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

307 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
GEP analysis validates high risk MDS and acute myeloid leukemia post MDS mice models and highlights novel dysregulated pathways.
Guerenne L, Beurlet S, Said M, Gorombei P, Le Pogam C, Guidez F, de la Grange P, Omidvar N, Vanneaux V, Mills K, Mufti GJ, Sarda-Mantel L, Noguera ME, Pla M, Fenaux P, Padua RA, Chomienne C, Krief P. Guerenne L, et al. Among authors: pla m. J Hematol Oncol. 2016 Jan 27;9:5. doi: 10.1186/s13045-016-0235-8. J Hematol Oncol. 2016. PMID: 26817437 Free PMC article.
DNA-mediated adjuvant immunotherapy extends survival in two different mouse models of myeloid malignancies.
Le Pogam C, Patel S, Gorombei P, Guerenne L, Krief P, Omidvar N, Tekin N, Bernasconi E, Sicre F, Schlageter MH, Chopin M, Noguera ME, West R, Abu A, Mathews V, Pla M, Fenaux P, Chomienne C, Padua RA. Le Pogam C, et al. Among authors: pla m. Oncotarget. 2015 Oct 20;6(32):32494-508. doi: 10.18632/oncotarget.5572. Oncotarget. 2015. PMID: 26378812 Free PMC article.
BCL-2 Inhibitor ABT-737 Effectively Targets Leukemia-Initiating Cells with Differential Regulation of Relevant Genes Leading to Extended Survival in a NRAS/BCL-2 Mouse Model of High Risk-Myelodysplastic Syndrome.
Gorombei P, Guidez F, Ganesan S, Chiquet M, Pellagatti A, Goursaud L, Tekin N, Beurlet S, Patel S, Guerenne L, Le Pogam C, Setterblad N, de la Grange P, LeBoeuf C, Janin A, Noguera ME, Sarda-Mantel L, Merlet P, Boultwood J, Konopleva M, Andreeff M, West R, Pla M, Adès L, Fenaux P, Krief P, Chomienne C, Omidvar N, Padua RA. Gorombei P, et al. Among authors: pla m. Int J Mol Sci. 2021 Sep 30;22(19):10658. doi: 10.3390/ijms221910658. Int J Mol Sci. 2021. PMID: 34638998 Free PMC article.
BCL-2 inhibition with ABT-737 prolongs survival in an NRAS/BCL-2 mouse model of AML by targeting primitive LSK and progenitor cells.
Beurlet S, Omidvar N, Gorombei P, Krief P, Le Pogam C, Setterblad N, de la Grange P, Leboeuf C, Janin A, Noguera ME, Hervatin F, Sarda-Mantel L, Konopleva M, Andreeff M, Tu AW, Fan AC, Felsher DW, Whetton A, Pla M, West R, Fenaux P, Chomienne C, Padua RA. Beurlet S, et al. Among authors: pla m. Blood. 2013 Oct 17;122(16):2864-76. doi: 10.1182/blood-2012-07-445635. Epub 2013 Aug 13. Blood. 2013. PMID: 23943652 Free PMC article.
BCL-2 and mutant NRAS interact physically and functionally in a mouse model of progressive myelodysplasia.
Omidvar N, Kogan S, Beurlet S, le Pogam C, Janin A, West R, Noguera ME, Reboul M, Soulie A, Leboeuf C, Setterblad N, Felsher D, Lagasse E, Mohamedali A, Thomas NS, Fenaux P, Fontenay M, Pla M, Mufti GJ, Weissman I, Chomienne C, Padua RA. Omidvar N, et al. Among authors: pla m. Cancer Res. 2007 Dec 15;67(24):11657-67. doi: 10.1158/0008-5472.CAN-07-0196. Cancer Res. 2007. PMID: 18089795
Localization of the NRAS:BCL-2 complex determines anti-apoptotic features associated with progressive disease in myelodysplastic syndromes.
Le Pogam C, Krief P, Beurlet S, Soulié A, Balitrand N, Cassinat B, Cavé H, Kosmider O, Setterblad N, Leboeuf C, Sarda-Mantel L, Hervatin F, Merlet P, Noguera ME, Janin A, Pla M, Fontenay M, Adès L, Fenaux P, Chomienne C, Padua RA, Omidvar N. Le Pogam C, et al. Among authors: pla m. Leuk Res. 2013 Mar;37(3):312-9. doi: 10.1016/j.leukres.2012.10.018. Epub 2012 Nov 12. Leuk Res. 2013. PMID: 23153525
pVAX14DNA-mediated add-on immunotherapy combined with arsenic trioxide and all-trans retinoic acid targeted therapy effectively increases the survival of acute promyelocytic leukemia mice.
Patel S, Guerenne L, Gorombei P, Omidvar N, Schlageter MH, Alex AA, Ganesan S, West R, Adès L, Mathews V, Krief P, Pla M, Fenaux P, Chomienne C, Padua RA. Patel S, et al. Among authors: pla m. Blood Cancer J. 2015 Dec 11;5(12):e374. doi: 10.1038/bcj.2015.102. Blood Cancer J. 2015. PMID: 26657197 Free PMC article. No abstract available.
DNA vaccination with all-trans retinoic acid treatment induces long-term survival and elicits specific immune responses requiring CD4+ and CD8+ T-cell activation in an acute promyelocytic leukemia mouse model.
Furugaki K, Pokorna K, Le Pogam C, Aoki M, Reboul M, Bajzik V, Krief P, Janin A, Noguera ME, West R, Charron D, Chomienne C, Pla M, Moins-Teisserenc H, Padua RA. Furugaki K, et al. Among authors: pla m. Blood. 2010 Jan 21;115(3):653-6. doi: 10.1182/blood-2007-08-109009. Epub 2009 Nov 19. Blood. 2010. PMID: 19965687 Free article.
307 results